HCI Equity Partners to sell SDS Rx to DHL Supply Chain

HCI Equity Partners to sell SDS Rx to DHL Supply Chain

DHL Supply Chain has agreed to acquire SDS Rx, a U.S. healthcare-transportation specialist backed by HCI Equity Partners, for an undisclosed sum . The German logistics company, formerly known as Deutsche Post, aims to enhance its life sciences and healthcare capabilities through this acquisition.

SDS Rx specializes in last-mile delivery, a critical stage in the healthcare supply chain. By integrating this service, DHL will be present at every stage of the supply chain, a field where it sees significant growth opportunities. Specialty pharmacies handling complex and expensive medicines for serious or rare diseases already account for 50% of U.S. prescription drug spending, and the number of patients they serve grew by 12% between 2018 and 2022 .

This acquisition is DHL's second healthcare-related deal in 2025. Earlier this year, DHL acquired CryoPDP, a specialty courier focused on clinical trials, biopharmaceuticals, and cell and gene therapies .

HCI Group, the parent company of SDS Rx, has seen its Relative Strength (RS) Rating improve to 91, reflecting a strong price performance over the last 52 weeks . The RS Rating, which ranges from 1 to 99, indicates that HCI Group's stock has outperformed most other stocks in the database. Despite a decline in EPS growth from 47% to 23%, the company's top line rose from 5% to 8% in the latest report .

This acquisition is a strategic move for DHL to strengthen its position in the healthcare logistics sector, as it continues to expand its services and capabilities.